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(53.6%). Multivariable analysis suggested that PCI treatment was the important
inﬂuential factors of usage rates of evidence-based drugs in secondary prevention.
The results showed that the nonuse rates of evidence-based drugs were 30% higher
for ACEI or ARB and b receptor blockers, 60% higher for statins, and 5-7 times
higher for antiplatelet agents in ACS patients without PCI treatment than those with
PCI treatment.
Conclusions: In China, more than 90% of hospitalized patients with ACS had one or
more major risk factors. There is still scope for improvement in the application of
drugs recommended by guidelines, especially for ACS patients without PCI
treatment.
GW25-e1116
Analysis of aspirin regimen of general practitioners for patients with Coronary
Heart Disease or Ischemic Cerebrovascular Disease in Beijing
Zuo Huijuan, Liu Jing, Wang Jinwen, Liu Jun, Wang Miao
Beijing Institute of Heart, Lung & Blood Vessel Diseases, Beijing Anzhen Hospital
afﬁliated to the Capital University of Medical Sciences
Objectives: Aspirin can signiﬁcantly decrease the risk of recurrence events for pa-
tients with cardiovascular disease (CVD), while PURE study indicated only few in-
dividuals with CVD took aspirin (15.5%) in communities of China. So a project
initiated by Beijing Municipal Health Bureau to assess the key knowledge on aspirin
use for GPs and the real statue of antithrombolic therapy in communities in Beijing.
Methods: This cross-sectional study was conducted in 10 community health centers
from 10 different districts in Beijing. A total of 207 GPs were recruited to collect the
key knowledge about aspirin use. 459 patients aged 30 to 89 years who visited the
GPs from the later August to the later September were identiﬁed as CHD and ICVD. A
standardized regimen questionnaire and key knowledge questionnaire was ﬁnished by
physicians.
Results: 312 patients (70%) were prescribed aspirin by GPs, it was high in patients
with unstable angina (80.8%), and low in patients with TIA (60.4%). Patients with
Ischemic stroke, stable angina, after bypass surgery or PCI, both CHD and ICVD
had the similar rate in 69.8%, 65.4%, 65.2% and 70.1%. 147 patients were not
prescribed aspirin, among them, 60 patients (40.8%) had a rest of medicine, 43
patients (29.3%) were thought as no need to use aspirin by GPs, and 30(20.4%)
patients were worried about its side-effects. Other reasons included gastrointestinal
reaction, light bleeding, peptic ulcer and high level BP. The utility rate of aspirin
was 80.0% (372/459). It was 84.1% in patients with CHD, 86.2% in patients with
Ischemic stroke, 77.9% in patients with both CHD and ICVD, and 60.4% in pa-
tients with TIA. It was lower in patients both with CHD and ICVD than patients
with CHD only, so advanced analysis was conducted in total of 17 patients with
CHD and ICVD no use aspirin; there were 6 (35.2%) patients because of worrying
about side-effects or being thought as no need to take aspirin by GPs. We also
analyzed the reasons why patients with TIA didn’t take aspirin, 10 (47.6%) pa-
tients were thought as no need to take aspirin by GPs and 11 (52.4%) patients were
worried about side-effects. Most of GPs knew patients with ACS, CHD and
Ischemic stroke should use aspirin with the percentage of 94.2%, 89.4% and
97.1%, but only 65.7% of GPs knew patients with TIA should use aspirin also.
Dosage regimen: The dosage of aspirin was 100 mg daily for all patients on the
prescription. About half of doctors suggested their patients taking medicine after
meal, 5.8% of doctors did not give any suggestion, and 2.9% of doctors did not
know how to give suggestion. About half (52.7%) of doctors suggested their
patients taking medicine on evening.
Conclusions: The rate of aspirin use was relative high in patients visiting the general
practitioners normally. The dosage of aspirin was rational. GPs’ knowledge and
adherence to the guideline played an important role on the utility rate of aspirin
especially in patients with TIA and stable angina.
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Investigation of coronary heart disease secondary prevention and standardized
follow-up
Gong Yanjun, Yang Fan, Huo Yong, Hong Tao
Peking University ﬁrst hospital
Objectives: To reveal the current status and effectiveness of follow-up on secondary
prevention of coronary heart disease (CHD) at Peking University First Hospital.
Methods: The study population was from Peking University First Hospital, one of
19 hospitals in the eleventh 5-year national key technologies R&D program for
coronary heart disease (CHD) secondary prevention research. This study of CHD
secondary prevention, conducted in China, aimed to standardize management of
CHD secondary prevention and improve adherence to secondary prevention guide-
lines and regular follow-up. The study group comprised 496 patients diagnosed with
CHD from January 1, 2007 to December 31, 2009 after a standardized follow-up
program began. A group of 300 CHD patients diagnosed with CHD from January 1,
2004 to December 31, 2004 were evaluated as control group. Study group partici-
pants were followed-up every 3 months for at least 1 year in the outpatient
department and interviewed by telephone from November 2012 to January 2013.
Data on control of risk-factors, medical therapy, and clinical events were collected.
Risk factors control and medications were compared between study group and
control group.
Results: Of the 496 patients enrolled in study group, 360 were male (72.6%), and the
age was 63.510.2 years (range, 24-85 years). The average duration of follow-up wasC104 JACC Vol 64/16/Suppl C j October 164.6 years (range, 3.5-6.0 years). At discharge, 75.4% of study group patients had
ceased smoking, 51.4% exercised regularly, 42.4% were overweight, 56.7% had blood
pressure <140/90 mmHg (<130/80 in those with diabetes mellitus), 51% had serum
low-density-lipoprotein cholesterol <2.60 mmol/L and 64.2% had fasting plasma
glucose <6.11 mmol/L. Antiplatelet medication was used by 99.4% of study group
patients, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers by
64.5%, beta-blockers by 79.1%, and statins by 94.3%. Major adverse cardiac events
(MACEs), the primary clinical outcome, occurred in 22.7% at the end of follow-up.
The proportions of quitting smoking (82.2% vs 73.7%, P¼0.014), control of serum
lipids (84.4% vs 45.6%, P¼0.000) and statin use (92.5% vs 54.3%, P¼0.000) at the
end of follow-up were signiﬁcantly greater in the study group than in the control
group.
Conclusions: Although a standardized follow-up program improved CHD secondary
prevention, some CHD patients still did not achieve the goals of lifestyle change, risk
factor control, and medication therapy.
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Aquired Long QT Syndrome May Contribute to the All Cause Mortality in
Hospitalized Patients-A Pilot Study
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Objectives: Though it is well-known that markedly prolonged QT interval (QTc500
ms) is an independent risk factor for sudden death and a predictor for all-cause car-
diovascular mortality and stroke, acquired QT syndrome (ALQTS) in the hospital
setting has long been overlooked.This study is to determine the prevalence of
QTc500 ms in hospitalized patients and their outcomes.
Methods: Electronic Medical Records of all hospitalized patients in one study center
were retrieved from January 1-21, 2014 with the inclusion criterion of QTc500 ms
and QRS duration 120 ms. Clinical evaluation included the diagnosis, presence of
electrolyte imbalance, renal dysfunction, the use of QT prolonging drugs and
outcomes.
Results: QTc500 ms was found in 2.6% (106/4121) of hospitalized patients. Among
them (age 66.614.4 years, female 58%), 71% were admitted to non-cardiology
departments. The use of diuretics and QT prolonging drugs (1) were seen in 51%
and 38%. Hypokalemia (serum K+<3.5 mmol/L ) was present in 33% and hypocal-
cemia (serum Ca2+<2.1mmol/L ) in 55%, respectively. In the ALQTS cohort, 7.5%
developed syncope/life-threatening arrhythmias and the 3-month all-cause mortality
was 13%. In latter, hypocalcemia was present 71% (10/14).
Conclusions: ALQTS with markedly prolonged QT intervals is 52 times higher
(2.6%) than that of congenital form (0.05%). In the hospital setting the majority of
ALQTS is seen in non-cardiology serves. The 3-month all-cause mortality is up to
13% in the ALQTS cohort. Hypocalcemia is the most common electrolyte imbalance
in patients with the worst outcome. Further investigation is underway to determine
whether a hospital-wide QTc500 ms alert system could prevent life-threatening
arrhythmia and sudden death in inhospital patients.
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Pentraxin-3 is associated with long-term adverse cardiovascular events in
patients with chronic heart failure.
Liu Haibo1,2, Wang Chunming1, Yu Wangjun1, Liu Yanhong1, Fang Yu1,
Bao Yingchun1, Zhang Limei1, Cao Yong1, Ge Junbo2
1Department of Cardiology, Yinzhou People’s Hospital, Ningbo University,
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Objectives: Pentraxin-3 (PTX3) is a novel inﬂammatory marker and a member of
pentraxin superfamily including C-reactive protein (CRP) and PTX3 is thought to
be more speciﬁc to cardiovascular inﬂammation than CRP, but its long-term
prognostic value in patients with chronic heart failure remains unclear. This study
was to evaluate the long-term prognostic value of PTX3 in patients with chronic
heart failure.
Methods: A total of 406 consecutive patients with chronic heart failure were pro-
spectively enrolled in this study for clinical 2-year follow-up. Plasma levels of PTX3
were determined in the second morning after hospitalized. Adverse cardiovascular
events were monitored as endpoints, the major endpoints included all-caused death
and re-hospitalization for worsening heart failure, the secondary endpoints included
acute myocardial infarction, stoke and peripheral arterial embolism.
Results: 376 patients have been followed-up for 2-year, 171 patients experienced
adverse cardiovascular events. The levels of PTX3 were signiﬁcantly and positively
associated with the severity of heart failure according to NYHA class (P<0.01).
Plasma PTX3 levels in patients with adverse cardiovascular events were signiﬁ-
cantly higher than those without (3.9110.83 ng/ml .vs 3.0880.99 ng/ml;
P<0.01), and the cardiac event rate was higher in patients with increased PTX3
(median value 3.438 ng/ml) than patients below median value (63.5% .vs 27.3%;
P<0.01). A Kaplan-Meier analysis revealed that patients with increased PTX3
(3.438 ng/ml) had a higher risk for adverse cardiovascular events than those–19, 2014 j GW-ICC Abstracts/Epidemiology, Prevention and Control
without (P<0.01). COX proportional hazards model of multi-factor analysis showed
that increased PTX3 was an independent risk factor for adverse cardiovascular
events in patients with chronic heart failure (relative risk (RR)¼4.224, P<0.01; 95%
CI 1.130-15.783).
Conclusions: PTX3 levels were positively and signiﬁcantly associated with the
severity of heart failure. Chronic heart failure patients with increased PTX3 had a
higher risk of developing adverse cardiovascular events. Increased PTX3 was
probably the long-term independent predictor for patients with chronic heart
failure.
GW25-e1609
The effects of Ginkgo biloba extract on the parameters of prothrombotic state - a
meta-analysis
Sun Jian1, Li Zhongdong2, Gou Xuerui1, Shi Erlan1, Wang Jianchang1
1Geriatrics Research Center, General Hospital of Air Force, PLA, 2Department of
Pharmacology, General Hospital of Air Force, PLA
Objectives: To evaluate the effects of a single dose of Ginkgo biloba extract on the
parameters of prothrombotic state (PTS).
Methods: Database including MEDLINE, EMBASE, Cochrane Library, The
Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature
Database (CBM), China National Knowledge Infrastructure (CNKI) and Wanfang
Data were searched from inception to April 2014. Randomized controlled trials
(RCTs) involving the healthy volunteers or patients receiving ginkgo biloba extract as
compared with placebo were included. Parameters of the prothrombotic state
including: platelet aggregation, activated partial thromboplastin time (APTT), pro-
thrombin time (PT), plasma ﬁbrinogen, blood viscosity, blood ﬂow velocity. Risk of
bias of allocation sequence, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting, and other biases were assessed by the Cochrane risk
of bias assessment tool. The data was analyzed by the Cochrane collaboration’s
RevMan 5.0. The following statistical methods were used: weighted mean difference
(WMD), standardized mean difference (SMD) and 95% conﬁdence intervals (CIs).
The results of the heterogeneity of the included studies were statistically homogeneous
(P>0.1, I2 <50%), the ﬁxed effect model was used for Meta analysis; there is sta-
tistical heterogeneity such as the testing results (P<0.1, I2>50%), then ﬁnd out the
heterogeneous sources according to the sensitivity analysis, subgroup analysis or
meta-regression analysis.
Results: Fourteen RCTs from ten countries with 440 participants were analyzed.
Ginkgo biloba extract group has signiﬁcant improvements in the partial parameters of
prothrombotic state as compared with placebo group. The result showed that Aden-
osine 5’-diphosphate (ADP)-induced platelet aggregation was signiﬁcantly inhibited
[WMD -7.53%, 95%CI (-14.27, -0.78), P¼0.03], the blood viscosity was signiﬁcantly
reduced [WMD-1.40mPa$s, 95%CI (-1.91, -0.89), P<0.00001], and the blood ﬂow
was increased [SMD 0.63, 95%CI (0.17, 1.09), P¼0.008]. However, there were no
signiﬁcant differences observed between GBE and placebo treatments in APTT
[WMD -0.25s, 95% CI (-0.68, 0.19), P¼0.26], PT [WMD -0.07s, 95% CI (-0.37,
0.23), P¼0.64], plasma ﬁbrinogen [WMD -4.94 mg/dl, 95% CI (-23.02, 13.15),
P¼0.59].
Conclusions: Based on the result of Meta-analysis about the parameters of pro-
thrombotic state, Ginkgo biloba extract may signiﬁcantly reduce blood viscosity and
also increase blood ﬂow velocity as compared with placebo. GBE may signiﬁcantly
improve the partial parameters of prothrombotic state and inhibit the formation of
thrombus.
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Chlorogenic acid prevents Isoproterenol-induced myocardial hypertrophy in
mice in vivo
Li Xucheng, Li Yanfei, Wu Jing, Li Jue
Tongji University
Objectives: Cardiac hypertrophy is an independent risk factor for cardiovascular
disease and its subsequent progression to heart failure represents a major cause of
morbidity and mortality all over the world. Chlorogenic acid (CGA) is an important
component of Chinese herbal medicine, which has a wide range of biological activity,
but the effct of CGA on heart in vivo is still unclear. The purpose of this research is to
investigate that whether CGA has a protective effect on isoproterenol-induced
myocardial hypertrophy in mice in vivo.
Methods: Mice were subcutaneously injected with normal saline or 1, 5and 10mg/
kg/day CGA for 3 days, and the next day treated with normal saline or 30mg/kg/
day isoproterenol for 7 days. All mice were detected by Vevo 770 ultrasonic
diagnostic apparatus. Both heart weight and body weight were measured in the
end. Both left ventricle and heart were made into Parafﬁn sections which were
stained by HE.
Results: In 5 and 10 mg/kg/day CGA groups EF value and FS value were signiﬁ-
cantly increased, however the heart weight index is signiﬁcantly decreased comparing
with normal saline group. According to the biopsy, left ventricular posterior wall
(LVPW) in experimental group decreased and cardiac chambers became larger
comparing with normal saline group.
Conclusions: This study mainly reveals that CGA is helpful to heart, and it has a
signiﬁcant protective effect on myocardial hypertrophy in vivo.JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/EGW25-e4202
Analysis for readmission of the heart failure patients
Liu Jingbo, Zhang Guangwei
Department of Cardiology, the ﬁrst hospital of Jilin Univercity
Objectives: Heart failure (HF) affects many people worldwide, and it is generally
expected that the number of people with HF will increase because of the aging
population and better survival rates of patients after a myocardial infarction. Read-
mission rates usually vary between 25% and 50% within 6 months after the ﬁrst
hospitalization for HF and account for approximately 70% of the costs. Despite efforts
to improve outcomes in heart failure (HF), readmission rates remain relatively high.
Reasons for readmission from different perspectives (patient, caregiver, health care
providers) may help to optimize the future management of patients with HF. The aims
of this study are to :1) gain insight into reasons for HF readmission from the
perspective of patients, caregivers, cardiologists, and HF nurses; 2) examine simi-
larities and differences in perspectives on the reason for an HF readmission, and 3)
describe possibilities to prevent an HF readmission from different perspectives.
Methods: A descriptive design was used with data from a substudy of the Coordi-
nating study evaluating Outcomes of Advising and Counseling in Heart failure
(COACH), a multicenter study on the effects of education and counseling in HF.
Between November 2010 and May 2013, 918 patients from the ﬁrst hospiltal of Jilin
Univercity were included in the COACH study. Inclusion criteria were hospitalization
for symptomatic HF, conﬁrmed by the cardiologist, and underlying heart disease as the
cause of HF. Exclusion criteria were an invasive intervention within the last 6 months
or planned in the next 3 months, participation in a study requiring additional visits to a
research nurse, and evaluation for heart transplantation. After written informed consent
to participate in the study, patients were followed for a period of 18 months. Patients
were randomized to 1 of 3 study groups: basic support, intensive support, or control.
Results: Data on reasons for readmission were collected on 173 readmissions. Per-
spectives of patients, caregivers, cardiologists, and HF nurses were collected by
interview and questionnaire. Worsening HF as the sole reason for readmission was
reported most often; however, 36% of caregivers, 56% of patients, and 63% to 65% of
health care providers indicated that other factors, such as comorbidity, nonadherence,
and nonoptimal medication, were important contributing factors. In only 34% of
readmissions, patients and their caregivers agreed with health care providers on the
underlying reason. Respondents reported that 23% to 31% of the readmissions could
probably have been prevented if adherence were higher, patients requested help
earlier, and adequate multidisciplinary professional help were available.
Conclusions: Firstly, to prevent future readmissions of patients with HF, it is
important to fully understand the reasons for readmission by gaining insight on the
reason for readmission from different perspectives. Adding information from different
perspectives provides a complete picture of reasons for the adverse outcome. Secondly,
we may need another approach to prevent adverse outcomes in which other medical
problems and new strategies, such as telemedicine or other home-based interventions
to improve adherence have to be considered. Finally, insufﬁcient professional help,
nonadherence, and knowledge deﬁcit were reported moreoften in the control group as a
precipitating factor for readmission than in the intensive treatment group.
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The increased visceral fat thickness in NAFLD patients enhances the risk of
coronary artery stenosis (CAS)
Cai He, Cao Pengyu, Zhang Xinying, Zheng Yang
The ﬁrst hospital of jilin university
Objectives: Recent studies have shown that NAFLD may be closely related with
CAS. In this research, By measuring the visceral fat thickness (VFT), it include the fat
of epicardial, before the liver, Around the kidney, Next to the kidney, and evaluating
the severity of CAS (according to coronary angiography), we want exploring the
relationship between NAFLD, VFT and the severity of CAS.
Methods: (1) The relationship between NAFLD, VFT and severity of CAS (323). By
coronary angiography, the subjects were divided into three groups as bellow, the
normal group (without stenosis), the moderate stenosis group (the target lesions less
than 75%), the severe stenosis Group (the target lesions more than 75%).The number
and VFT of each group in NAFLD patients were measured. (2) The correlation be-
tween NAFLD and VFT in the severe stenosis group (197). The severe stenosis group
was divided into two groups that NAFLD group and non NAFLD group, according to
coronary score, each group was divided into 3subgroups (3-6, 6-10, more than 10
points). The VFT of each group was measured.
Results: (1) Along with the increasing degree of CAS, the proportion of NAFLD was
signiﬁcantly increased by 16% and 19% (the moderate stenosis was 71%, the severe
stenosis was 74%) than in the normal group(without coronary artery stenosis was
55%), the total VFT also increase, especially the epicardial layer (the moderate ste-
nosis increased by 23% and the severe stenosis increased by 54%). (2) In the severe
CAS group, the patients were divided into NAFLD group and non NAFLD group.
compared with non NAFLD group, the fat of epicardial, before the liver, Around the
kidney, Next to the kidney and the coronary score signiﬁcantly increased in the
NAFLD group (10%, 22%, 32%, 36% and 27%, respectively) .Along with the in-
crease of coronary score , the epicardial fat thickness was increased signiﬁcantly (16%
and 34%, respectively) in the non NAFLD group; but the epicardial thickness of the
NAFLD group was slightly increased (8% and 8%, respectively). In the two groups,
the VFT of the other three sections have no signiﬁcant change among the subgroups.pidemiology, Prevention and Control C105
